19results about How to "Increase secretion level" patented technology

The invention provides a tetrapeptide for promoting bone growth, the amino acid sequence of the tetrapeptide is Glu-Pro-Gly-Phe (EPGF), the molecular weight of the tetrapeptide is 448.48 Da, the tetrapeptide can be prepared from egg yolk protein through protease enzymolysis, separation and purification and can also be obtained through chemical solid-phase synthesis, and the tetrapeptide belongs to the technical field of functional bioactive peptides. The tetrapeptide prepared by the invention can promote the growth of osteoblasts in a body and improve the secretion level of insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1) and I-type procollagen amino terminal peptide (PINP) in cells, so that the effect of promoting bone growth is achieved, and a new functional component is provided for a product for improving bone growth.

The invention relates to the technical field of biological medicine, in particular to the field of cell therapy, and particularly relates to application of STAR and immune cells comprising the STAR to treatment and / or prevention of tumors, an antigen binding region of the STAR comprises one or more than two of an antibody, a ligand or an antibody fusion body which binds to LILRB4, the antibody such as scFv or VHH, and the ligand and the antibody fusion body can be combined with the LILRB4. Wherein the LILRB4 is used as a tumor antigen and / or a receptor in an immunosuppressive active cell. According to the invention, the targeted killing effect of immune cells on tumors is enhanced by targeting tumor cells and / or reducing immune escape caused by immunosuppressive active cells.

The invention discloses an application of enzymatic casein in promotion of porcine endocrine cell proliferation, belongs to the technical field of animal nutrition and feed, and provides an application of enzymatic casein in promotion of porcine endocrine cell proliferation, which does not aim at diagnosis and treatment of diseases. The invention provides a method for promoting pig endocrine cell proliferation by using casein enzymolysis. The method comprises the following steps: adaptively feeding pigs with daily ration with the crude protein content of 13% for 7 days; mixing the daily ration with the crude protein content of 13% with the enzymolysis casein according to the mass ratio of 95.5: 4.5 to obtain the daily ration containing the enzymolysis casein, and feeding twice a day for 28 days. According to the invention, a certain proportion of casein hydrolysate is added into the feed to regulate and control microbe composition of small intestinal mucosa of growing pigs, so that proliferation of small intestinal endocrine cells is further regulated, the secretion level of gastrointestinal hormone is increased, the gastrointestinal transport function of animals is finally enhanced, the absorption of nutrient substances is accelerated, and the growth performance of the pigs is improved.

The application belongs to the field of regenerative medicine and nano drug delivery system, and particularly relates to a drug-loaded exosome for improving the testosterone secretion capacity of testicular interstitial cells and a preparation method and application thereof. The application links a targeting FATE1 polypeptide to the surface of MSC-derived exosomes by a chemical coupling method, and loads a small molecule compound in the exosomes by electroporation, so as to obtain modified MSC-derived exosomes. The obtained exosomes can obtain the targeting capacity in testicular interstitial cells, and the natural repair capacity of MSC-derived exosomes and the release of small molecule drugs promote the repair of damaged cells, improve the testosterone secretion capacity of testicular interstitial cells, and relieve male erectile dysfunction caused by diseases or aging.

The application discloses application of a small-molecule compound targeting TIM-3 in tumor immunotherapy and relates to the technical field of immunology and antitumor drugs. The small-molecule compounds DTS and CT are safe and verified marketed drugs, and it is found that the small-molecule compounds can bind to TIM-3 protein and regulate T cell exhaustion related to TIM-3. + Experiments prove that DTS and CT can effectively inhibit CD8 T cell exhaustion, promote expansion of exhausted precursor T cells, and comprehensively enhance T cell antitumor immune function. In a melanoma model, the compounds significantly inhibit tumor growth and reduce the proportion of tumor-infiltrating T cell exhaustion. The application uses the strategy of "new use of old drugs", provides a TIM-3 small-molecule inhibitor with high safety, oral administration, strong penetration and low cost, effectively solves the clinical transformation predicament of existing antibody drugs and newly synthesized small molecules, and provides a new scheme for rapid transformation of tumor immunotherapy.

The present invention provides an epitope peptide of a RAS G13D mutant, an antigen presenting cell expressing the epitope peptide, a tumor vaccine containing the antigen presenting cell, and a use of the tumor vaccine in the prevention or treatment of a tumor having RAS G13D mutation. The present invention also provides a T cell receptor (TCR) specifically recognizing a RAS G13D mutant, a conjugate and a fusion protein containing the TCR, an immune cell expressing the TCR, a T cell drug containing the immune cell, and a use of the T cell drug in the prevention or treatment of a tumor having RAS G13D mutation.

The invention belongs to the technical field of medicine. More specifically, the invention relates to application of telbivudine in preparation of drugs for preventing or treating breast cancer. The invention provides an application of telbivudine in preparation of a medicine for preventing or treating breast cancer. The invention proves that the telbivudine has an anti-breast cancer effect for the first time, and the telbivudine as the NSD2 inhibitor can effectively inhibit the growth of the breast cancer. Meanwhile, the telbivudine can remodel the immunosuppressive tumor microenvironment, reduce the infiltration of regulatory T cells (Treg), and significantly enhance the effector function of CD8 + T cells. More importantly, the telbivudine and the PD-1 antibody are combined to show a remarkable synergistic effect in a breast cancer mouse model, and the tumor inhibition effect and survival benefit are superior to those of a single drug. The combination scheme of the telbivudine and the PD-1 antibody significantly improves the sensitivity of breast cancer to immunotherapy, provides a new scheme for solving the problem of low clinical response rate of breast cancer immunotherapy, and has good application prospects and application values.

The invention relates to a method for improving the secretory expression level of expansin in bacillus subtilis, and aims to provide a method capable of promoting the bacillus subtilis to secrete expansin (microorganism-derived expansin BsEXLX1 and plant-derived expansin LeEXP2). The method comprises the following steps: firstly, screening a promoter capable of efficiently starting expansin to construct an engineering strain, and then performing overexpression of a secretory cofactor in the strain to improve the limitation of target protein in the aspects of secretory transport, folding maturation, stability and the like, thereby improving the extracellular secretion level of the two expansin. Amplification verification is carried out through a 5L fermentation tank, the secretion level of expansin is further improved, the expression quantity of BsEXLX1 protein is improved to 1.3 g / L, and the secretion quantity of LeEXP2 is improved to 43.7 mg / L. And a process basis and industrialization potential are provided for subsequent large-scale fermentation production and application development.

The technical scheme of the present application discloses a plastic film for providing high-quality light environment, which comprises the following components in parts by weight: 9,9-dianthraquinone 4-5 parts, pyrene anthrone 6-7.5 parts, anthracene-D10 4-6 parts, auxiliary agent 7.2-10.6 parts, and resin 70-80 parts. The preparation method comprises the following steps: S1, uniformly mixing 9,9-dianthraquinone, pyrene anthrone and anthracene-D10, heating to melting in an oxygen-free reaction kettle, cooling, and then crushing by a high-speed pulverizer to obtain a powder with a particle diameter of less than 100 nm; S2, mixing the powder with the auxiliary agent in a double-screw extruder, and then shearing and granulating to obtain a high-quality light environment additive master batch; and S3, mixing the high-quality light environment additive master batch with the resin, and preparing a plastic film by a flow casting and rolling process or a blowing process. The prepared plastic film effectively improves the photosynthetic rate of plants and significantly improves the quality and yield of plants.

The present invention belongs to the field of biomedicine technology. More specifically, it relates to a method for preparing NK cells with high cytotoxic activity and its use in preparing tumor immunotherapy drugs. The present invention first discovered that a polypeptide with an amino acid sequence of MPYSTELIFYIEMDP has the effect of enhancing the cytotoxic activity of NK cells. In a co-culture experiment, the polypeptide showed the effect of promoting NK cell proliferation and increasing the level of IFN-γ secretion of NK cells. It was found in a mouse subcutaneous tumor model that the polypeptide has the effect of significantly inhibiting the growth of mouse subcutaneous tumors, and it is suggested that the polypeptide may exert its anti-tumor activity by promoting the secretion of IFN-γ.

The invention relates to the field of medicines, in particular to application of allicin or a precursor or a derivative thereof to preparation of a medicine for treating CFTR-mediated diseases. The invention further discloses application of the allicin or the precursor or the derivative of the allicin to preparation of the CFTR activating agent or the CFTR correcting agent. According to the present invention, the first research results show that allicin can activate the CFTR channel function in a dose-dependent manner: opening the CFTR channel; 2, correction of CFTR channel dysfunction: the positioning efficiency of a CFTR subunit membrane can be improved by protecting the completeness of a CFTR subunit, so that allicin or a precursor or a derivative thereof can be used for preparing a CFTR activator or a CFTR corrector, the insulin secretion level can be improved through a CFTR channel, and the allicin or the precursor or the derivative thereof can be used for treating pancreatic insufficiency.

The invention discloses an in-vitro human ovarian granular cell pan-apoptosis model and a construction method thereof, and belongs to the field of reproductive medicine. According to the invention, hungry-treated human ovarian granulosa cells are cultured by using a culture medium containing LPS and IFN-gamma, such that the human ovarian granulosa cell pan-apoptosis model is obtained. The constructed human ovarian granular cell pan-apoptosis model has pan-apoptosis key characteristics such as apoptosis, pyroptosis and necrotic apoptosis at the same time, and can be used as a cell model for researching a pathological mechanism of polycystic ovarian syndrome. The invention establishes a good foundation for researching the pathogenic mechanism of pan-apoptosis on polycystic ovarian syndrome.

The invention discloses a preparation method and application of elaeagnus angustifolia gum homogeneous polysaccharide. The method comprises the following steps: removing impurities from elaeagnus angustifolia gum, crushing, and extracting with pure water; precipitating the extracting solution with ethanol to obtain crude elaeagnus angustifolia gum polysaccharide; loading the crude polysaccharide on an ion exchange chromatography column for elution, and collecting the polysaccharide at the elution part with water; freeze-drying to obtain polysaccharide at the neutral part of elaeagnus angustifolia gum; and loading the neutral part polysaccharide sample on a gel chromatographic column for purification, eluting with water, collecting the peak top end, and freeze-drying to obtain the elaeagnus angustifolia gum homogeneous polysaccharide. The obtained elaeagnus angustifolia gum homogeneous polysaccharide is a white flaky flocculate, the molecular weight is 158.8 * 10 < 4 > Dalton, the purity is high, monosaccharide is composed of rhamnose, arabinose, xylose, mannose and galactose, and detection shows that the elaeagnus angustifolia gum homogeneous polysaccharide has remarkable immunoregulation and antioxidant activity, and can be used for preparing the immunopotentiator. The compound can be used as an immunomodulatory component or / and an antioxidant active component for preparing health care products and food, and has wide application prospects and market value.

This invention relates to a Kunitz-type potato trypsin inhibitor mutant, its preparation method, and its applications, belonging to the fields of genetic engineering and protein engineering modification technology. Based on a wild-type potato trypsin inhibitor, this invention constructs the mutant shown in SEQ ID NO.3. This mutant exhibits 5.67 times higher trypsin inhibitory activity than the wild type, and in animal models, it increases cholecystokinin (CCK) secretion levels by 1.94 times and reduces food intake by 44.58%. The Kunitz-type potato trypsin inhibitor mutant provided by this invention can serve as an active ingredient and has significant application potential in biomedicine and food health fields, particularly in regulating appetite and alleviating obesity.

The invention discloses a bispecific antibody targeting to B7H3 and 4-1BB and an application of the bispecific antibody. The invention provides a bispecific antibody targeting B7H3 and 4-1BB. The bispecific antibody is formed by connecting a 4-1BB antigen binding domain to C ends of two heavy chains of an anti-B7H3 antibody respectively; the 4-1BB antigen binding structural domain is a single-chain antibody for resisting 4-1BB, and comprises a heavy chain variable region for resisting the 4-1BB antibody and a light chain variable region for resisting the 4-1BB antibody. The bispecific antibody provided by the invention shows a good in-vitro tumor cell killing effect and an in-vivo tumor inhibition effect, so that the bispecific antibody provided by the invention has important significance and application potential when being used for preparing antibody targeted drugs.

The invention provides recombinant lactobacillus casei for expressing toxoplasma gondii SAG2A protein as well as a construction method and application of the recombinant lactobacillus casei, and relates to the technical field of genetic engineering. The recombinant lactobacillus casei for genetically expressing the toxoplasma gondii SAG2A protein is constructed by connecting a toxoplasma gondii SAG2A gene segment with a lactic acid pPG612.1 vector segment lactic acid bacteria secretory expression vector. Experiments prove that the SAG2A gene can be stably inherited, and the protein can be successfully expressed in recombinant lactobacillus casei. The recombinant lactobacillus casei can colonize and secrete toxoplasma gondii SAG2A protein in the intestinal tract of a mouse for a long time, the IgA secretion level of the intestinal tract of the mouse is improved, a specific SAG2A protein antibody is generated, and mucosal immunity is enhanced; the proliferation activity of splenocytes is improved, and the IL-10 level in serum is improved. The recombinant lactobacillus casei has huge potential in resisting toxoplasmosis.

The present invention provides a novel therapeutic means that is relatively low invasive and capable of exerting a desired therapeutic effect on diabetes including T1D. Specifically, an agent for protecting and / or regenerating a pancreatic β cell in a mammal with diabetes is provided, which contains a nucleic acid encoding a heparin-binding epidermal growth factor-like growth factor (HB-EGF), wherein the agent is systemically administered. The aforementioned preparation in combination with a nucleic acid encoding hepatocyte growth factor (HGF) is also provided.

The invention provides a synthetic method of mammary epithelial cell casein regulated and controlled by gene and signal channels, which comprises the following steps: 1, cell culture and proliferation: selecting mammary epithelial cells, adding 10% of fetal calf serum (FBS) and 1% of antibiotics into a basic culture medium, and culturing to 80% of confluence degree; the second step, specific allogenic substances and valine are added, specifically, the specific allogenic substances and valine are further added into the culture medium, culture continues to be conducted for 48 hours, it is ensured that the gene is fully expressed, and the specific allogenic substances specifically comprise a CSN1S1 interference agent, an mTOR signal channel accelerant and diallyl disulfide; and step 3, cell treatment and sample collection. According to the method, the casein synthesis rate of the mammary epithelial cells can be increased; and the total amount of casein synthesized by mammary epithelial cells is increased.

The invention belongs to the technical field of extraction and preparation of natural products, and discloses camellia seed cake polysaccharide with immunological enhancement and antioxidant activity as well as a preparation method and application of the camellia seed cake polysaccharide. The method comprises the following steps: extracting camellia seed cake polysaccharide by adopting an ultrasonic-assisted method and a water extraction and alcohol precipitation method, determining the content of crude polysaccharide by adopting a phenol-sulfuric acid method, desalting, removing impurities, purifying and grading the camellia seed cake crude polysaccharide by adopting a DEAE-Sepharose FF ion exchange column and a Chromdex 75PG gel filter column to obtain camellia seed cake pure polysaccharide, and determining the molecular weight of the polysaccharide by adopting an exclusion chromatography method. And finally, determining the structure of the compound through chemical methods such as high performance liquid chromatography, full methylation combined gas chromatography-mass spectrometry, infrared spectroscopy, nuclear magnetic resonance and the like, a chromatographic method and a spectrum method. In-vitro experiments and in-vivo experiments prove that the camellia seed cake polysaccharide has immunological enhancement and antioxidant activity at the same time, and can be widely applied to the fields of medicines, daily chemical products, feeds and the like.